awmsg logo



melatonin (Slenyto®)


Reference No. 3947


Appraisal information

melatonin (Slenyto®) 1 mg prolonged-release tablet
melatonin (Slenyto®) 5 mg prolonged-release tablet


Company: Flynn Pharma Ltd
BNF category: Central nervous system
NMG meeting date: 09/10/2019
AWMSG meeting date: 13/11/2019
   
   
Submission Type: Full Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and/or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient